Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go:
Extended
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go:
Extended
investment:
£10,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
mylearnadfriend has created on-line Learning software for direct sale to businesses and organisations across all skill sectors.
please watch video for details about this learning portal
days to go:
Expired
investment:
£5,800
AxiaFunder is a commercial litigation funding platform that offers investors access to pre-vetted cases. The platform aims to connect eligible investors like sophisticated retail investors, high-net-worth, and typically institutions with claimants seeking funding. Launched in January 2019 with the first case fully funded within seven days and the third in 7 hours; 5 cases financed to date, attracted over 355 registered investors so far including several institutions and has featured in several prominent publications including the Financial Times, Times and City AM. Also, they have won the 'Best Commercial Litigation Crowdfunding Platform 2019' award by Wealth & Finance. AxiaFunder plans to use the proceeds to make key hires particularly to strengthen its case origination, further development of its platform and marketing to build the AxiaFunder brand and grow its investor base.
days to go:
Expired
investment:
£256,780
Peliwica Insurance is set up to disrupt the current rural, equine, and agriculture insurance broker markets. It is a new Insuretech business that was launched in 2018. In the same year, the company gained its first FCA Approval and the Lloyds CoverHolder status that held the key enablers to launch this business. Peliwica Insurance is trading with 10 Brokers with a £100m premium opportunity. With its upcoming mobile application and devised white-labelled D2C platforms, the company will be able to allow brokers to access new product markets and customers more effectively.
days to go:
Expired
investment:
£75,980
MergerLinks is a platform where global dealmakers can connect and identify with transaction counterparts based on their relationships and credentials. The company collates proprietary and public transactions data and assembles it into an information tool. MergerLinks also forms an ecosystem where clients can easily access advisory services. This is done by contacting and identifying people with the right skill set and network. Most of the revenue generated by MergerLinks comes from the sale of B2B subscriptions to a range of connectivity and data tools. With the proceeds, the company will market its premium subscriptions, build the network of content distribution partners, and build Customer Success function.
days to go:
Expired
investment:
£239,270
